Quantcast

Pii produce FDA-approved Academic Pharmaceuticals’ Bretylium Tosylate Injection drug

Pharmaceutics International, Contract Development and Manufacturing Organization (CDMO) headquartered in Hunt Valley, Maryland, will produce Bretylium Tosylate for Academic Pharmaceuticals, as it received FDA approval of Bretylium Tosylate Injection USP.

Academic is currently seeking a commercial partner to license and launch the drug product in the U.S, Pii said in a statement Wednesday.

Bretylium Tosylate Injection is indicated for the prophylaxis and therapy of ventricular fibrillation; treatment of life-threatening ventricular arrhythmia that has failed to respond to first-line antiarrhythmic agents.

Dr. Syed Abidi, Pii’s Chairman and CEO said: “We are pleased to gain approval of this additional therapy to treat ventricular fibrillation offering health care providers alternative options to treat this life-threatening condition.  Bretylium Tosylate Injection USP, 500 mg/10 mL is the 11th FDA product approval and 3rd injectable product approval, for Pii and its partners, during the past two years.  This most recent approval follows the tentative approval of the first syringe product filed from Pii, thus expanding Pii’s injectable product offering to include terminally sterilized vials, aseptically filled vials, and syringe products. Bretylium Tosylate is a uniquely effective agent for the treatment of ventricular tachycardia and ventricular fibrillation in a cardiac arrest.  It is the only drug that can pharmacologically convert ventricular fibrillation, it is an alternative to Amiodarone and more effective than Lidocaine,” added Dr. John Somberg, President of Academic Pharmaceuticals, Inc.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.